SMMT
HealthcareSummit Therapeutics Inc.
$17.44
$-0.08 (-0.46%)
Jan 5, 2026
Price History (1Y)
Analysis
Summit Therapeutics Inc. is a healthcare company operating in the biotechnology industry. The company has a significant market presence with a market capitalization of $12.98 billion and approximately 159 employees. The financial health of Summit Therapeutics Inc. is characterized by negative profitability metrics, with gross margin, operating margin, and profit margin all at 0.0%. The company's returns on equity and assets are also negative, at -292.5% and -152.9%, respectively. On the balance sheet side, the company has a debt-to-equity ratio of 2.82 and a cash position of $238.55 million. Summit Therapeutics Inc.'s valuation is marked by negative forward P/E and EV/EBITDA ratios, at -17.39 and -13.70, respectively. The price to book ratio is 67.60.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Summit Therapeutics Inc.
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida.
Visit website →Key Statistics
- Market Cap
- $12.98B
- P/E Ratio
- N/A
- 52-Week High
- $36.91
- 52-Week Low
- $15.55
- Avg Volume
- 2.84M
- Beta
- -1.51
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- United States
- Employees
- 159